Онкогематология (Sep 2014)

Invasive aspergillosis: results of multicenter study

  • N. N. Klimko,
  • O. V. Shadrivova,
  • S. N. Khostelidi,
  • E. A. Desyatik,
  • Yu. V. Borzova,
  • R. M. Chernopyatova,
  • E. V. Shagdileeva,
  • A. G. Volkova,
  • M. O. Popova,
  • I. S. Zyuzgin,
  • O. S. Ruzhinskaya,
  • O. Ye. Ryabykina,
  • N. V. Medvedeva,
  • A. S. Kolbin,
  • E. G. Boychenko,
  • T. S. Bogomolova,
  • S. M. Ignatieva,
  • L. S. Zubarovskaya,
  • B. V. Afanasiev

Journal volume & issue
Vol. 9, no. 2
pp. 13 – 19

Abstract

Read online

We present the results of a multicenter study of 445 patients with “proven” and “probable” invasive aspergillosis (EORTC/MSG, 2008). Invasive aspergillosis usually occurs in patients with hematological malignancies (88 %), main underlying diseases were acute myeloid and acute lymphoblastic leukemia. The risk factors: prolonged agranulocytosis (64 %), cytostatic chemotherapy (57 %), corticosteroid treatment (45 %), and allogeneic hematopoietic stem cells transplantation (29 %). The pathogens – A. fumigatus (42 %), A. niger (33 %), and A. flavus (21 %). The main site of infection were lungs (86 %). 12 week overall survival was 83 %. Bronchoscopy use for the early diagnosis (p = 0.01), adequatetherapy with voriconazole (p = 0.002) and secondary antifungal prophylaxis (p = 0.0003) were positive prognostic factors for survival of patients with invasive aspergillosis.

Keywords